Actively Recruiting
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
Led by University of Illinois at Chicago · Updated on 2026-04-06
27
Participants Needed
1
Research Sites
357 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being done to see if the addition of a targeted form of radiation to standard conditioning regimen will increase the amount of cancer cells that are killed off in the bone marrow and reduce the chances that your disease may return. This description is called Intensity Modulated Total Marrow Irradiation (IM-TMI).
CONDITIONS
Official Title
BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Related donor who is at least Human Leukocyte Antigen (HLA) haploidentical or mismatched unrelated donor
- Diagnosis of relapsed or refractory acute leukemia including AML or ALL in second remission or primary refractory leukemia
- Poor-risk AML in first remission including AML from MDS or myeloproliferative disorder, or with poor-risk molecular or cytogenetic features
- Poor-risk ALL in first remission with specified cytogenetic or molecular features, high white blood cell counts, age over 35, or poor minimal residual disease clearance
- Myelodysplastic syndromes (MDS) with poor-risk features such as specific cytogenetics, IPSS score INT-2 or higher, treatment-related or secondary MDS, diagnosis before age 21, lack of response to DNA-methyltransferase inhibitors, severe cytopenias, or poor-risk molecular mutations
- Mixed lineage and biphenotypic leukemia
- Adequate organ function including left ventricular ejection fraction 40% or higher, bilirubin 2.0 mg/dL or lower (unless Gilbert's syndrome or hemolysis), ALT and AST less than 5 times the upper limit of normal, and lung function (FEV1 and FVC) above 50% of predicted
You will not qualify if you...
- Significant co-morbidities including left ventricular ejection fraction below 40%
- Bilirubin levels above 2.0 mg/dL (unless due to Gilbert's syndrome or hemolysis) and ALT or AST more than 5 times the upper limit of normal
- Lung function (FEV1 and FVC) below 50% of predicted or DLCO below 50% corrected for anemia
- Karnofsky performance score below 70
- History of cirrhosis
- Unable to provide informed consent
- Prior radiation to more than 20% of bone marrow-containing areas as assessed by radiation oncology physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Illinois Cancer Center
Chicago, Illinois, United States, 60612
Actively Recruiting
Research Team
R
Rondelli Damiano, MD
CONTACT
M
Marisol Vega, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here